Piscataway, NJ, September 4, 2024 – Camber Pharmaceuticals is pleased to announce the addition of Decitabine for Injection to its product line.
Decitabine for Injection is a nucleoside metabolic inhibitor indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high risk International Prognostic Scoring System groups.
Decitabine for Injection is available in 50 mg strength per single-dose vial.
To learn more about Decitabine for Injection, please visit https://www.camberpharma.com/decitabineforinjection
